ArticleBlood cancer journal2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.
Abstract read
In one paragraph
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
- PPRC1 is a prognostic biomarker and key regulator of mitochondrial oxidative phosphorylation in multiple myeloma.Annals of medicine · 2026Article
- Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma.Biomarker research · 2026Article
- Next-generation sequencing-based high-risk genomic stratification in multiple myeloma.Translational cancer research · 2026Article
- Targeting ADAR1 Restores Interferon Signaling and Enhances Immunotherapy Response in Multiple Myeloma.International journal of molecular sciences · 2026Article
- Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma.International journal of molecular sciences · 2026Review
- Advances in immune microenvironment profiling during multiple myeloma progression and therapy.International journal of hematology · 2026Review
- Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.Haematologica · 2026Article
- Network-Based Bioinformatics Reveal Microenvironment-Driven Cell-to-Cell Communication in the Progression of Multiple Myeloma.International journal of molecular sciences · 2026Article
- Mapping of Neutrophils in Cancers: Insights From Spatial Omics Technologies.European journal of immunology · 2026Review
- Single-cell profiling reveals MIF-mediated immune evasion and CD8 + T cell exhaustion in relapsed multiple myeloma.Clinical and experimental medicine · 2026Article
- An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies.Clinical and experimental medicine · 2026Review
- Immune heterogeneity at diagnosis influences treatment response and survival in multiple myeloma.Discover oncology · 2026Article
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- Differential expression of immune activation markers in T cells from patients with multiple myeloma.Frontiers in oncology · 2026Article
- UAP1 as a prognostic biomarker regulating malignant biological functions in multiple myeloma cells.Frontiers in oncology · 2026Article
- Single-cell RNA sequencing analysis revealed a potential association between ELK3 expression and the progression of multiple myeloma.Frontiers in immunology · 2026Article
- CyTOF profiling of bone marrow immune dynamics across myeloma stages.Oncoimmunology · 2025Article
- Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance.Blood cancer journal · 2025Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Yan Cheng *Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0001-7877-9622
Fumou Sun *Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0003-2034-3492
Daisy V AlapatDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Visanu WanchaiMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0003-2243-3838
David MeryMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Eric R SiegelDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0001-9824-6612
Hongwei XuMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Sarah JohnsonMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Wancheng GuoMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Clyde BaileyMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Cody AshbyDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0002-9361-0283
Michael Anton BauerDepartment of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0003-2498-7295
Samer Al HadidiMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0003-4297-8042
Carolina SchinkeMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0002-2699-1741
Sharmilan ThanendrarajanMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Maurizio ZangariMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Frits van RheeMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID 0000-0001-9959-1282
Guido TricotMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
John D ShaughnessyMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. JDShaughnessy@uams.edu.
Fenghuang ZhanMyeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. Fzhan@uams.edu.ORCID 0000-0001-5417-2973
Funding
Prevention of MGUS Progression to MM by Modulating the Bone Marrow MicroenvironmentU54CA272691 · NCI · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI Yong Li · 2023 to 2026
$6.1MTowards a better understanding of the critical role and therapeutic potential of drug resistant genes in multiple myelomaR01CA236814 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI FENGHUANG ZHAN · 2020 to 2026
$2.5MInstitutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3MAutomated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health RecordR42CA180190 · NCI · CLINACUITY,INC. · PI MEYSTRE, STEPHANE · 2016 to 2017
$1.5MAutomated Dynamic Lists for Efficient Electronic Health Record ManagementR41CA180190 · NCI · CLINACUITY,INC. · PI MEYSTRE, STEPHANE · 2013 to 2014
$422kCharacterize Drug Resistance in Multiple MyelomaI01BX006235 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI FENGHUANG ZHAN · 2025 to 2026
–BLRD VA I01 BX006235NCATS NIH HHS KL2 TR003108NCI NIH HHS R01 CA236814NCI NIH HHS R41 CA180190NCI NIH HHS R42 CA180190NCI NIH HHS U54 CA272691U.S. Department of Defense (United States Department of Defense) CA180190U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1R01CA236814-01A1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 3R01-CA236814-03S1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54CA272691-01
Abstract
Tumor immune microenvironmental alterations occur early in multiple myeloma (MM) development. In this study, we aim to systematically characterize the tumor immune microenvironment (TME) and the tumor-immune interactions from precursor stages, i.e., monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM), to newly diagnosed MM, comparing these to healthy donors. Using CIBERSORT, mass cytometry (CyTOF), and single-cell RNA sequencing (scRNA-Seq), we examined innate and adaptive immune changes across these stages. We found a decrease in granulocytes in the TME predicts MM outcomes. HLA-DR is reduced in CD16
Indexed as
Multiple MyelomaTumor MicroenvironmentCD8-Positive T-LymphocytesFemaleHumansKiller Cells, NaturalMaleMonoclonal Gammopathy of Undetermined SignificanceMultiomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.